Get 40% Off
🤯 This Tech Portfolio is up 29% YTD! Join Now to Get April’s Top PicksGet The Picks – Just 99 USD

Bristol-Myers plans to divest Celgene's psoriasis drug

Published 06/24/2019, 11:55 AM
Updated 06/24/2019, 11:55 AM
© Reuters. FILE PHOTO: Logo of global biopharmaceutical company Bristol-Myers Squibb is pictured on the blouse of an employee in Le Passage

© Reuters. FILE PHOTO: Logo of global biopharmaceutical company Bristol-Myers Squibb is pictured on the blouse of an employee in Le Passage

(Reuters) - Bristol-Myers Squibb (NYSE:BMY) Co on Monday offered to divest Celgene (NASDAQ:CELG) Corp's psoriasis treatment Otezla to allay concerns raised by the U.S. competition regulator, and pushed back the closing of their $74 billion deal.

The surprise move sent Bristol's shares down 4.3% in morning trading, while Celgene fell nearly 4%.

Bristol announced its plans to buy Celgene in a cash-and-stock deal in early January to bring together the companies that specialize in oncology and cardiovascular drugs in the largest pharmaceutical industry merger ever. It had said it would close the deal in the third quarter of 2019.

However, now it expects the merger to close by the end of 2019 or the beginning of 2020.

The divestiture is subject to further review by the U.S. Federal Trade Commission (FTC) and requires Bristol to enter into a consent decree with the agency, Bristol said.

In March, the FTC had sought additional information from the companies as it focused on their psoriasis treatments as part of its review of their planned merger.

Otezla brought in revenue of $1.61 billion for Celgene in 2018. Bristol is also developing a treatment for the condition and in September reported positive results from a mid-stage trial of its plaque psoriasis drug.

"The company is continuing to develop its promising immunology pipeline asset, tyrosine kinase 2 (TYK2) inhibitor, in several autoimmune diseases, including psoriasis," Bristol said in a statement.

Jefferies analyst Michael Yee said the divestiture came as a surprise to the brokerage and can be seen as a sign that the FTC is being tougher on regulating competition.

Bristol said it remains actively engaged in discussions with the FTC on continued review of its offer to buy Celgene.

Separately on Monday, Bristol said its blockbuster cancer treatment Opdivo failed to meet the main goal of statistically significant improvement in overall survival in patients in a late-stage study.

© Reuters. FILE PHOTO: Logo of global biopharmaceutical company Bristol-Myers Squibb is pictured on the blouse of an employee in Le Passage

The companies have submitted a formal application for the merger clearance by the European Commission, Bristol said.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.